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Abstract
The factors associated with the progression of ductal carcinoma in
situ (DCIS) to invasive breast cancer are poorly understood. Many
studies of this subject focus on the role of molecular and genetic
alterations in the neoplastic epithelial cells. However, emerging
evidence suggests that transition from DCIS to invasive cancer is
strongly dependent upon alterations in the microenvironment. The
potential roles of myoepithelial cells and of stromal-epithelial
interaction are of particular interest in this regard.
In a study published previously in Breast Cancer Research,
Castro and colleagues [1] compared the gene expression
signatures of epithelial cells isolated by laser capture micro-
dissection (LCM) from non-neoplastic breast tissue, pure
ductal carcinoma in situ (DCIS), DCIS associated with
invasive breast cancer, and invasive breast cancer. They
found that the expression signature of cells derived from
DCIS associated with invasive breast cancer was very similar
to that of cells of invasive carcinomas, but differed sub-
stantially from cells of pure DCIS.
The observation by Castro and colleagues that cells derived
from DCIS associated with invasive cancers show many
similarities at the level of gene expression with cells derived
from invasive cancers [1] are consistent with the results of
prior studies in which the expression signatures of DCIS and
invasive cancers were compared. In those studies, very few
genes were found to be differentially expressed in DCIS and
invasive breast cancers, particularly those of similar grade,
and these studies were unable to define signatures that
distinguished between DCIS and invasive cancer [2,3]. The
results of these prior studies suggest that the most dramatic
changes in gene expression occur during the transition from
normal epithelium to DCIS rather than in the transition from
DCIS to invasive breast cancer. The finding of Castro and
colleagues that pure DCIS and DCIS associated with
invasive cancer showed a substantial number of differentially
expressed genes is of interest and appears to be at odds
with this concept. However, these results must be interpreted
with caution since only five cases of pure DCIS were studied.
Furthermore, these five cases of pure DCIS consisted of a
relatively homogenous group of primarily large lesions with
high grade nuclei and HER2 overexpression that were
compared to a more heterogenous group of DCIS associated
with invasive cancer [1].
Castro and colleagues propose two possible explanations for
the observation that neoplastic cells of DCIS show con-
siderable molecular overlap with cells of invasive breast cancer
[1]. The first possible explanation is that only a small number of
genes is associated with the progression of DCIS to invasive
breast cancer. The second explanation proposed is that the
major molecular alterations associated with invasion are
manifested before there is morphologic evidence of invasion at
the level of the light microscope. Both of these explanations
focus on alterations in the neoplastic epithelial cells as the key
determinants of the transition from in situ to invasive breast
cancer. An alternative, albeit not mutually exclusive, explanation
is that the progression of DCIS to invasive breast cancer is
strongly dependent upon microenvironmental factors, perhaps
even more so than on genetic or molecular changes in the
neoplastic epithelial cells themselves. In fact, there is now a
growing body of evidence supporting a critical role for the
tumor microenvironment in breast cancer progression even in
its earliest, pre-invasive stages. Components of the
microenvironment that have received particular attention in this
regard are myoepithelial cells (MECs) and stromal cells (that is,
fibroblasts and myofibroblasts).
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MECs surround mammary ducts and lobular acini and have
important roles in normal mammary gland development and
physiology  [4,5]. In addition, MECs have natural tumor
suppressor functions, including maintenance of the basement
membrane, providing a physical barrier between epithelial
cells and the surrounding stroma, and maintenance of
epithelial cell polarity. Furthermore, experimental evidence has
indicated that MECs produce factors that, through paracrine
effects, inhibit tumor growth, invasion and angiogenesis [6].
While MECs are retained around ductal-lobular spaces
containing DCIS, recent molecular studies have indicated
that MECs that surround spaces involved by DCIS differ
substantially from normal MECs in several respects [6-9].
When compared to normal MECs, DCIS-associated MECs
show downregulation of a variety of genes involved in normal
functions, including those for oxytocin receptor, laminin and
thrombospondin, and upregulation of genes for chemokines
that enhance epithelial cell proliferation, migration, invasion
and stromal angiogenesis, such as SDF1/CXCL12 and
CXCL14. DCIS-associated MECs also show increased levels
of enzymes involved in the degradation of extracellular matrix,
such as matrix metalloproteinases [7]. In addition, a recent
study utilizing methylation-specific digital karyotyping demon-
strated distinct epigenetic changes in DCIS-associated
MECs [9]. Further, the results of several studies have shown
that DCIS-associated MECs show immunophenotypic
differences from MECs in normal breast tissue. For example,
Hilson and colleagues [10] found that expression of MEC
markers such as smooth muscle myosin heavy chain, CD10
and cytokeratin 5/6 was reduced in the MECs surrounding
DCIS in over 80% of the cases evaluated when compared
with MECs in normal breast tissue. Taken together, these
results provide strong evidence that, in many cases of DCIS,
the associated MECs are abnormal. These findings raise the
possibility that the progression of DCIS to invasive breast
cancer may, at least in part, be due to MEC abnormalities that
result in a loss of their normal tumor suppressor functions [5,6].
Other factors in the microenvironment may also be important
in regulating the transition from DCIS to invasive breast
cancer, such as stromal-epithelial interactions. Stromal cells
influence growth, differentiation, invasive behavior and
polarity of normal breast epithelial cells and breast cancer
cells in vitro and in vivo [11]. In addition, stromal alterations
similar to those seen in invasive breast cancers are already
evident in association with some cases of DCIS and even in
some benign lesions such as radial scars. These include stromal
angiogenesis, increased stromal cell expression of mRNAs for
various extracellular matrix components, and increased stromal
cell expression of proteases and cytokines [12-14].
The molecular determinants of the transition from in situ to
invasive carcinoma in the breast remain to be more clearly
elucidated. One approach to address this issue is that used
in the study of Castro and colleagues, that is, to utilize LCM
to isolate ‘pure’ populations of epithelial cells and to evaluate
molecular alterations in these cells [1]. However, it should be
noted that even when LCM is used, it is not possible to
reliably separate epithelial cells from MECs and differences in
gene expression between groups (particularly between non-
neoplastic breast tissue and DCIS) could well reflect
differences in expression of MEC-associated genes rather
than epithelial cell-associated genes. Moreover, focusing on
changes in the epithelial cells, while important, is tantamount
to viewing only one side of a coin. Studies addressing this
important question should not ignore the other side of the
coin, that is, the potentially important role of the
microenvironment in regulating the progression of DCIS to
invasive breast cancer.
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